Noramco is moving forward with a broad offering of clinical- to commercial-scale cannabinoid APIs for branded and generic pharmaceuticals. The comprehensive offering includes everything a drug manufacturer requires to advance cannabinoid-based APIs to finished dosage forms.
Working remotely in Scotland, but thinking globally, Stuart Mackinnon builds relationships within Noramco and with external partners to align and secure the long-term requirements of customers in Europe, the Middle East, Africa, and Asia (EMEA).
“As our business becomes global, it’s essential to expand the scope of our collaboration to determine the best routes to market…”
Thinking three steps ahead, Chang Cheng looks after the needs of customers months or even years in advance of product deliveries. Keeping a steady eye on the development and production cycle of certain APIs, Chang makes it possible for generic and branded pharmaceutical compounders to acquire a secure, steady supply of high-quality controlled substances…
Research and logistics professionals responsible for Noramco’s European operations now operate out of a new facility in Neuhausen, Switzerland. Approximately 30 employees work at the state-of-the-art center…
Researchers at Noramco study analytical methods to detect and determine the presence of potentially genotoxic impurities (PGIs) in pharmaceutical products.
Why is Noramco leveraging expertise in APIs to provide solutions to stability, bioavailability, and purity challenges?
Meet us at CPhI Worldwide for more information about “one-stop API development and manufacturing.”